Aurora Advanced Flow Cytometry System from Cytek Biosciences Continues to Gain Traction
Patented, Unique, Differentiated Solution Embraced by Researchers around the Globe
FREMONT, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- First introduced in June of last year, the Aurora advanced flow cytometry system from Cytek Biosciences Inc. has gained significant traction in the scientific community - and is setting the new standard for what is possible. Aurora has now been sold into four continents - Asia, North America, Australia, and Europe. Cytek's mission is to fill a gap in the industry by making high-dimensional flow cytometry accessible to a larger number of researchers - and the company has its sights set on the remaining three continents.
Its superb performance has enabled the possibility of new discoveries and deeper biological insights at an affordable cost. Unlike other spectral flow cytometers, Aurora is a full spectrum flow cytometer based on Cytek's innovative architecture that does not use any optical dispersive element in its fluorescence detection system. The use of multiple excitation lasers enable Aurora's collection optics system to cover the entire luminescence emission window - from ultraviolet to infrared. By employing solid state detector arrays as opposed to conventional PMT detectors, Aurora is able to be packaged in a compact platform with excellent sensitivity. This enhanced sensitivity allows for the co-labeling of cells using dyes with highly overlapping spectral profiles and the resolution of dim and rare populations. More than 20-color labels are achievable with only three onboard lasers at 405 nm, 488 nm and 640 nm. This Cytek innovative technology is covered by pending patent applications, the most recent of which published on January 25, 2018.
Reflecting on the state of flow cytometry today, Dr. Wenbin Jiang, CEO of Cytek Biosciences, noted that, "Traditionally, the flow cytometry industry has been monopolized by a few large players with little motivation to innovate. Most flow cytometers on the market are based on 20-year-old technology that fails to meet today's application requirements. For example, applications in the field of immuno-oncology require the use of many colors from a single sample. Conventional flow cytometer designs try to meet this requirement by merely adding excitation laser wavelengths in the infrared and ultraviolet, which significantly increased the cost of ownership and complicated maintenance and usage. If you look at the telecom industry as a counterpoint, it is quickly apparent that - after the demise of the old monopoly - innovation has flourished, leading to today's IT and cloud services that have positively impacted lives the world over." Dr. Jiang, himself a veteran of the telecom industry, is an inventor who holds close to 100 U.S. patents.
Under the leadership of Dr. Jiang, Cytek has meshed innovative telecom technology with its 25 years of experiences in flow cytometer advancement, leading to the all-new full spectrum flow cytometer, Aurora. "Aurora has now been sold into four continents and has leapfrogged competing solutions to satisfy long unmet needs in fields of research such as immuno-oncology, systems biology, extracellular vesicles, stem cells and genomics," continued Dr. Jiang. "We hear from our customers that other solutions have fallen well short of their expectations, and that Aurora is the cytometer that they have been waiting for."
Please visit www.cytekbio.com for more information on Aurora and to learn more about Cytek's lineup of flow cytometry solutions, all of which are backed by comprehensive service plan offerings.
About Cytek Biosciences
Cytek is a leading flow cytometry solution provider and provides compact, affordable instruments with high multiplexing capability and a wide range of services to support researchers and clinicians. Cytek Biosciences Inc. is the outcome of a merger between Cytek Development Inc., a leading pioneer in flow cytometry, and Cytoville Inc., a venture-capital-backed business focusing on advanced bio-medical instrument technology development. The company's headquarters are in Fremont, California with branch offices and distribution channels across the globe. To learn more, visit www.cytekbio.comand follow them on LinkedIn.
Lages & Associates
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cytek Biosciences via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Comodo CA Sees 35 Percent Year-Over-Year Increase in EV Certificates22.3.2018 15:47 | Pressmeddelande
EV SSL will be a topic of discussion at the Comodo CA booth during RSA 2018 CLIFTON, N.J., March 22, 2018 (GLOBE NEWSWIRE) -- Comodo CA, a worldwide leader in digital identity solutions, will address evolving cyberthreats and the increasing importance Extended Validation (EV) TLS/SSL certificates play in securing websites and inspiring consumer trust at the RSA Conference 2018, San Francisco, April 16 - 20. According to the Feb 2018 Netcraft report, Comodo CA has seen a 35 percent year-over-year increase of EV certificate units* making it one of the fastest growing providers of high assurance certificates. The volume of EV certificates globally also saw a record year in 2017 as more and more businesses adopt EV as standard practice for their websites. The demand for stronger, more secure EV certificates comes in the wake of increased phishing websites using Domain Validated (DV) certificates. Phishing websites imitate legitimate websites to steal customers' funds and identities. Phishi
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody22.3.2018 14:43 | Pressmeddelande
SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today a strategic licensing agreement with CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies. The agreement gives CBT exclusive world-wide development and commercialization rights to a novel, recombinant, human monoclonal antibody which targets a differentiated epitope on the cytotoxic T-lymphocyte antigen-4 (CTLA-4) molecule. Binding of this antibody to CTLA-4 blocks the interaction of CTLA-4 with its ligands CD80/CD86 thus allowing the cytotoxic T cells to function actively. Under the terms of this global licensing agreement, CBT gain
Cloudflare Announces Mobile SDK to Monitor Network Performance for Applications22.3.2018 14:00 | Pressmeddelande
New free solution delivers network analytics to any mobile app developer SAN FRANCISCO, March 22, 2018 (GLOBE NEWSWIRE) -- Cloudflare, the leading Internet performance and security company, today announced the Cloudflare Mobile SDK, a free solution that enables any mobile app developer to understand network performance and metrics. Consumers are frustrated by mobile apps that are slow, crash, or deliver errors that degrade the user experience. For mobile app developers, a bad user experience means poor reviews, lower engagement, and reduced conversion on business metrics. Delivering consistent app performance requires focusing on every link in the chain: app code, network calls between the app and edge networks, and server infrastructure. There are a number of solutions that give developers analytics on their applications, but there has never been a way for app developers to understand how often their apps fail due to network errors. App developers easily integrate the Cloudflare Mobil
Compuware: Survey Shows Critical Mainframe Workloads Increasing While Mainframe Staff Losses Remain Unfilled22.3.2018 13:00 | Pressmeddelande
Many Organizations Not Measuring, Prioritizing Vital Key Performance Indicators 57 percent of enterprises with a mainframe currently run more than half of their business-critical applications on the platform-with that number expected to increase to 64 percent by next year. 72 percent of customer-facing applications are completely or very dependent on mainframe processing. Enterprises have only replaced 37 percent of the mainframe workforce lost over the past five years. Many organizations surveyed are not currently measuring velocity or efficiency key performance indicators, putting them at a disadvantage in the digital age. DETROIT, March 22, 2018 (GLOBE NEWSWIRE) -- The mainframe is becoming more important to large enterprises, with the percentage of organizations running at least half their business-critical applications on that platform expected to increase next year. However, the loss of skilled mainframe staff, and the failure to subsequently fill these positions, pose significan
Hoylu AB: HOYLU NAMED A 2018 TOP 25 COLLABORATION TECHNOLOGY COMPANY BY CIO APPLICATIONS22.3.2018 08:30 | Pressmeddelande
Malmo, Sweden, March 6, 2018 - Hoylu, a leading enterprise collaboration company today announced that CIO Applications Magazine has named Hoylu a Top 25 Collaboration Technology Company in 2018. CIO Applications presents each year the most innovative and unique companies, highlighting companies that excel in the space of Enterprise Collaboration Products and Technology. The Hoylu Product Suite allows users to collaborate quickly and easily with anyone around the world using a freeform or structured canvas and the ability to share workspaces in real time on any device. Hoylu was selected from many companies worldwide as a result of their unique approach to collaboration, which puts emphasis on the experience and putting the user first. The award recognizes Hoylu as a company at the forefront of providing innovative collaboration solutions to help companies and individuals work better and smarter together. "We are honored to be recognized among the leaders in the category of collaboratio
Hoylu AB: Hoylu ett topp 25 företag 2018 inom samarbete och teknologi utmärkelse från CIO Applications.22.3.2018 08:30 | Pressmeddelande
Malmö, 22 mars 2018 - Hoylu, ett ledande företag för samarbetslösningar, tillkännagav idag att CIO Applications Magazine har givit Hoylu utmärkelsen topp 25 inom samarbete och teknologi 2018. CIO Applications presenterar varje år de mest innovativa och unika företagen, och belyser företag som utmärker sig inom Enterprise Collaboration Products och teknologi. Hoylu Product Suite gör det möjligt för användare att samarbeta snabbt och enkelt med någon annan i en annan del av världen med hjälp av en friformad eller strukturerad duk och möjligheten att dela arbetsytor i realtid på vilken enhet som helst. Hoylu plockades ut från många företag över hela världen till följd av deras unika samarbetssätt, vilket lägger tonvikten på upplevelsen och användarupplevelsen Priset ger Hoylu ett erkännande för att vara ett företag som ligger i framkant och som erbjuder innovativa samarbetslösningar för att hjälpa företag och privatpersoner att arbeta bättre och smartare tillsammans. "Vi är hedrade att bl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum